Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Assets Average (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed Assets Average for 5 consecutive years, with $245.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 31.72% to $245.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $245.5 million, a 31.72% decrease, with the full-year FY2025 number at $300.0 million, down 6.74% from a year prior.
  • Assets Average was $245.5 million for Q4 2025 at TScan Therapeutics, down from $280.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $361.4 million in Q3 2024 to a low of $158.9 million in Q3 2022.
  • A 5-year average of $252.2 million and a median of $251.0 million in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: skyrocketed 91.37% in 2023, then plummeted 31.72% in 2025.
  • TScan Therapeutics' Assets Average stood at $196.5 million in 2021, then fell by 7.24% to $182.3 million in 2022, then skyrocketed by 54.58% to $281.8 million in 2023, then grew by 27.61% to $359.6 million in 2024, then tumbled by 31.72% to $245.5 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Assets Average are $245.5 million (Q4 2025), $280.4 million (Q3 2025), and $315.6 million (Q2 2025).